🇺🇸 FDA

Drug profile · INN

lusutrombopag

MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI)

FDA: approved EMA: approved PMDA: approved B02BX
US status
approved
Patents linked
0
News articles
0

Quick answer

lusutrombopag (MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI)) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN lusutrombopag
Brand MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI)
Route ORAL
Formulation TABLET
ATC code B02BX

Frequently asked questions

What is lusutrombopag?

lusutrombopag (MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI)) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for lusutrombopag?

MULPLEO (PREVIOUSLY LUSUTROMBOPAG SHIONOGI) is a marketed brand name for lusutrombopag. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of lusutrombopag?

lusutrombopag has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.